Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00699374




Registration number
NCT00699374
Ethics application status
Date submitted
16/06/2008
Date registered
18/06/2008
Date last updated
14/01/2013

Titles & IDs
Public title
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Scientific title
A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma
Secondary ID [1] 0 0
A6181170
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Hepatocellular 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Liver

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - sunitinib malate
Treatment: Drugs - sorafenib

Experimental: Arm A - sunitinib arm

Active comparator: Arm B - sorafenib arm


Treatment: Drugs: sunitinib malate
sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.

Treatment: Drugs: sorafenib
sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
Secondary outcome [1] 0 0
Progression-Free Survival (PFS)
Timepoint [1] 0 0
Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
Secondary outcome [2] 0 0
Time to Tumor Progression (TTP)
Timepoint [2] 0 0
Baseline, every 4 weeks during treatment, every 8 weeks posttreatment up to Week 150
Secondary outcome [3] 0 0
European Quality of Life (EQ-5D)- Health State Profile Utility Score
Timepoint [3] 0 0
Day 1 of each cycle

Eligibility
Key inclusion criteria
* Histologically-confirmed diagnosis of hepatocellular carcinoma
* presence of measurable disease by radiographic imaging
* Child-Pugh class A
* ECOG PS 0 or 1
* adequate organ function.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior treatment with any systemic treatment for hepatocellular carcinoma
* prior local treatment within 4 weeks from entry
* presence of clinically relevant ascites
* severe hemorrhage <4 weeks of starting study treatment
* known HIV or serious acute or chronic illness
* current treatment on another clinical trial
* pregnancy or breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/07/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2011
Sample size
Target
Accrual to date
Final
1075
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Concord
Recruitment hospital [2] 0 0
Pfizer Investigational Site - Elizabeth Vale
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Woodville South
Recruitment hospital [4] 0 0
Pfizer Investigational Site - Melbourne
Recruitment hospital [5] 0 0
Pfizer Investigational Site - Parkville
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
5112 - Elizabeth Vale
Recruitment postcode(s) [3] 0 0
5011 - Woodville South
Recruitment postcode(s) [4] 0 0
3004 - Melbourne
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Iowa
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Tennessee
Country [9] 0 0
United States of America
State/province [9] 0 0
Virginia
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Belgium
State/province [11] 0 0
Bruxelles
Country [12] 0 0
Belgium
State/province [12] 0 0
Gent
Country [13] 0 0
Canada
State/province [13] 0 0
Alberta
Country [14] 0 0
Canada
State/province [14] 0 0
British Columbia
Country [15] 0 0
Canada
State/province [15] 0 0
Ontario
Country [16] 0 0
Canada
State/province [16] 0 0
Quebec
Country [17] 0 0
China
State/province [17] 0 0
Anhui
Country [18] 0 0
China
State/province [18] 0 0
Fujian
Country [19] 0 0
China
State/province [19] 0 0
Guangdong
Country [20] 0 0
China
State/province [20] 0 0
Guangxi
Country [21] 0 0
China
State/province [21] 0 0
Hubei
Country [22] 0 0
China
State/province [22] 0 0
Jiangsu
Country [23] 0 0
China
State/province [23] 0 0
Sichuan
Country [24] 0 0
China
State/province [24] 0 0
Zhejiang
Country [25] 0 0
China
State/province [25] 0 0
Beijing
Country [26] 0 0
China
State/province [26] 0 0
Bejing
Country [27] 0 0
China
State/province [27] 0 0
Chong qing
Country [28] 0 0
China
State/province [28] 0 0
Guangzhou
Country [29] 0 0
China
State/province [29] 0 0
Nanjing
Country [30] 0 0
China
State/province [30] 0 0
Shanghai
Country [31] 0 0
France
State/province [31] 0 0
Amiens Cedex 1
Country [32] 0 0
France
State/province [32] 0 0
Bordeaux Cedex
Country [33] 0 0
France
State/province [33] 0 0
Clichy Cedex
Country [34] 0 0
France
State/province [34] 0 0
Creteil Cedex
Country [35] 0 0
France
State/province [35] 0 0
Lille Cedex
Country [36] 0 0
France
State/province [36] 0 0
Nice Cedex 2
Country [37] 0 0
France
State/province [37] 0 0
Paris Cedex 13
Country [38] 0 0
France
State/province [38] 0 0
Paris
Country [39] 0 0
France
State/province [39] 0 0
St Herblain Cedex
Country [40] 0 0
France
State/province [40] 0 0
Strasbourg Cedex
Country [41] 0 0
France
State/province [41] 0 0
Toulouse
Country [42] 0 0
France
State/province [42] 0 0
Vandoeuvre Les Nancy Cedex
Country [43] 0 0
France
State/province [43] 0 0
Villejuif Cedex
Country [44] 0 0
Germany
State/province [44] 0 0
Hamburg
Country [45] 0 0
Germany
State/province [45] 0 0
Hannover
Country [46] 0 0
Germany
State/province [46] 0 0
Mainz
Country [47] 0 0
Germany
State/province [47] 0 0
Muenchen
Country [48] 0 0
Hong Kong
State/province [48] 0 0
Hong Hong
Country [49] 0 0
Hong Kong
State/province [49] 0 0
Kowloon
Country [50] 0 0
Hong Kong
State/province [50] 0 0
Shatin, New Territories
Country [51] 0 0
Hong Kong
State/province [51] 0 0
Tuen Mun, New Territories
Country [52] 0 0
Italy
State/province [52] 0 0
FC
Country [53] 0 0
Italy
State/province [53] 0 0
Bari
Country [54] 0 0
Italy
State/province [54] 0 0
Bologna
Country [55] 0 0
Italy
State/province [55] 0 0
Cattolica (RN)
Country [56] 0 0
Italy
State/province [56] 0 0
Milano
Country [57] 0 0
Italy
State/province [57] 0 0
Padova
Country [58] 0 0
Italy
State/province [58] 0 0
Pavia
Country [59] 0 0
Italy
State/province [59] 0 0
Ravenna
Country [60] 0 0
Italy
State/province [60] 0 0
Rimini
Country [61] 0 0
Japan
State/province [61] 0 0
Aichi
Country [62] 0 0
Japan
State/province [62] 0 0
Chiba
Country [63] 0 0
Japan
State/province [63] 0 0
Fukuoka
Country [64] 0 0
Japan
State/province [64] 0 0
Gifu
Country [65] 0 0
Japan
State/province [65] 0 0
Hokkaido
Country [66] 0 0
Japan
State/province [66] 0 0
Hyogo
Country [67] 0 0
Japan
State/province [67] 0 0
Ishikawa
Country [68] 0 0
Japan
State/province [68] 0 0
Nagasaki
Country [69] 0 0
Japan
State/province [69] 0 0
Osaka-fu
Country [70] 0 0
Japan
State/province [70] 0 0
Osaka
Country [71] 0 0
Japan
State/province [71] 0 0
Shizuoka
Country [72] 0 0
Japan
State/province [72] 0 0
Tokyo
Country [73] 0 0
Japan
State/province [73] 0 0
Okayama
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Chonbuk
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Gyeonggi-do
Country [76] 0 0
Korea, Republic of
State/province [76] 0 0
Jeollanam-do
Country [77] 0 0
Korea, Republic of
State/province [77] 0 0
Busan
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Daegu
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Incheon
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Seoul
Country [81] 0 0
Malaysia
State/province [81] 0 0
Kuala Lumpur
Country [82] 0 0
Malaysia
State/province [82] 0 0
Selangor
Country [83] 0 0
Philippines
State/province [83] 0 0
Cebu
Country [84] 0 0
Philippines
State/province [84] 0 0
Cebu City
Country [85] 0 0
Philippines
State/province [85] 0 0
Davao City
Country [86] 0 0
Philippines
State/province [86] 0 0
Manila
Country [87] 0 0
Philippines
State/province [87] 0 0
Quezon City
Country [88] 0 0
Poland
State/province [88] 0 0
Warszawa
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Chelyabinsk
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Pyatigorsk
Country [91] 0 0
Russian Federation
State/province [91] 0 0
St.Petersburg
Country [92] 0 0
Singapore
State/province [92] 0 0
Singapore
Country [93] 0 0
South Africa
State/province [93] 0 0
Parktown
Country [94] 0 0
Spain
State/province [94] 0 0
Barcelona
Country [95] 0 0
Spain
State/province [95] 0 0
Cantabria
Country [96] 0 0
Spain
State/province [96] 0 0
Illes Balears
Country [97] 0 0
Spain
State/province [97] 0 0
Murcia
Country [98] 0 0
Spain
State/province [98] 0 0
Sevilla
Country [99] 0 0
Sweden
State/province [99] 0 0
Linkoping
Country [100] 0 0
Taiwan
State/province [100] 0 0
Chai-Yi
Country [101] 0 0
Taiwan
State/province [101] 0 0
Taoyuan
Country [102] 0 0
Taiwan
State/province [102] 0 0
Changhua
Country [103] 0 0
Taiwan
State/province [103] 0 0
Kaohsiung
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taichung City
Country [105] 0 0
Taiwan
State/province [105] 0 0
Taichung
Country [106] 0 0
Taiwan
State/province [106] 0 0
Tainan
Country [107] 0 0
Taiwan
State/province [107] 0 0
Taipei
Country [108] 0 0
Thailand
State/province [108] 0 0
Bangkok
Country [109] 0 0
Thailand
State/province [109] 0 0
Chiang Mai
Country [110] 0 0
Turkey
State/province [110] 0 0
Ankara
Country [111] 0 0
Turkey
State/province [111] 0 0
Istanbul
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Cambridgeshire
Country [113] 0 0
United Kingdom
State/province [113] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.
Trial website
https://clinicaltrials.gov/study/NCT00699374
Trial related presentations / publications
Abuhelwa AY, Badaoui S, Yuen HY, McKinnon RA, Ruanglertboon W, Shankaran K, Tuteja A, Sorich MJ, Hopkins AM. A clinical scoring tool validated with machine learning for predicting severe hand-foot syndrome from sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2022 Apr;89(4):479-485. doi: 10.1007/s00280-022-04411-9. Epub 2022 Feb 28.
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013 Nov 10;31(32):4067-75. doi: 10.1200/JCO.2012.45.8372. Epub 2013 Sep 30.
Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovacs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00699374